Regions of recognition by blocking antibodies on the light chain of botulinum neurotoxin A. Antigenic structure of the entire toxin

Immunobiology

Volumn 216, Issue 6, 2011, Pages 698-706

  Dolimbek, Behzod Z ^a   Steward, Lance E ^b   Aoki, K Roger ^b   Atassi, M Zouhair ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ALLERGAN INC   (United States)

Author keywords

Antibodies; Antigenic sites; Botulinum neurotoxin A; Competition; Epitopes; Light chain; Synthetic peptides

Indexed keywords

BOTULINUM ANTISERUM; BOTULINUM TOXIN A; MAJOR HISTOCOMPATIBILITY ANTIGEN; TOXIN ANTIBODY;

ANTIBODY COMBINING SITE; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; EPITOPE MAPPING; HEAVY CHAIN; LIGHT CHAIN; MOLECULAR RECOGNITION; PEPTIDE MAPPING; PRIORITY JOURNAL; STRUCTURE ANALYSIS; TOXIN ANALYSIS; TOXIN STRUCTURE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BLOCKING; ANTIBODY SPECIFICITY; ANTIGENS; BOTULINUM TOXINS, TYPE A; MICE; MOLECULAR DYNAMICS SIMULATION; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN BINDING; PROTEIN CONFORMATION; SPECIES SPECIFICITY;

EID: 79955541733     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imbio.2010.10.010     Document Type: Article

References (51)

1. Adekar S.P., Takahashi T., Jones R.M., Al-Saleem F.H., Ancharski D.M., Root M.J., Kapadnis B.P., Simpson L.L., Dessain S.K. Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain. PLoS One 2008, 3(8):e3023.
2. Amersdorfer P., Wong C., Chen S., Smith T., Deshpande S., Sheridan R., Finnern R., Marks J.D. Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries. Infect. Immun. 1997, 65(9):3743-3752.
3. Atassi M.Z. Antigenic structure of myoglobin. The complete immunochemical anatomy of a protein and conclusions relating to antigenic structures of proteins. Immunochemistry 1975, 12(5):423-438.
4. Atassi M.Z. Antigenic structures of proteins. Their determination has revealed important aspects of immune recognition and generated strategies for synthetic mimicking or protein binding sites. Eur. J. Biochem. 1984, 145(1):1-20.
5. Atassi M.Z. Basic immunological aspects of botulinum toxin therapy. Mov. Disord. 2004, 19(Suppl. 8):S68-S84.
6. Atassi M.Z. On the enhancement of anti-neurotoxin antibody production by subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-hemagglutinin. Microbiology 2006, 152(Pt. 7):1891-1895.
7. Atassi M.Z., Dolimbek B.Z. Mapping of the antibody-binding profile on botulinum neurotoxin A HN-domain (residues 449-859) with anti-toxin antibodies from four host species. Antigenic profile of the entire H-chain of botulinum neurotoxin A. Protein J. 2004, 23(1):39-52.
8. Atassi M.Z., Oshima M. Structure, activity and immune (T and B cell) recognition of botulinum neurotoxin. Crit. Rev. Immunol. 1999, 19(3):219-260.
9. Atassi M.Z., Smith J.A. A proposal for the nomenclature of antigen sites in peptides and proteins. Immunochemistry 1978, 15(8):609-610.
10. Atassi M.Z., Manshouri T., Sakata S. Localization and synthesis of the hormone-binding regions of the human thyrotropin receptor. Proc. Natl. Acad. Sci. U.S.A. 1991, 88(9):3613-3617.
11. Atassi M.Z., Dolimbek B.Z., Hayakari M., Middlebrook J.L., Whitney B., Oshima M. Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855-1296 with anti-toxin antibodies from three host species. J. Protein Chem. 1996, 15(7):691-700.
12. Atassi M.Z., Dolimbek G.S., Deitiker P.R., Aoki K.R., Dolimbek B.Z. Submolecular recognition profiles in two mouse strains of non-protective and protective antibodies against botulinum neurotoxin A. Mol. Immunol. 2005, 42(12):1509-1520.
13. Atassi M.Z., Dolimbek B.Z., Jankovic J., Steward L.E., Aoki K.R. Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment. Mol. Immunol. 2008, 45(15):3878-3888.
14. Black J.D., Dolly J.O. Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves. J. Cell Biol. 1986, 103(2):521-534.
15. Breidenbach M.A., Brunger A.T. Substrate recognition strategy for botulinum neurotoxin serotype A. Nature 2004, 432(7019):925-929.
16. Byrne M.P., Smith L.A. Development of vaccines for prevention of botulism. Biochimie 2000, 82(9-10):955-966.
17. Chen S., Barbieri J.T. Unique substrate recognition by botulinum neurotoxins serotypes A and E. J. Biol. Chem. 2006, 281(16):10906-10911.
18. Cheng L.W., Stanker L.H., Henderson T.D., Lou J., Marks J.D. Antibody protection against botulinum neurotoxin intoxication in mice. Infect. Immun. 2009, 77(10):4305-4313.
19. Clayton M.A., Clayton J.M., Brown D.R., Middlebrook J.L. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect. Immun. 1995, 63(7):2738-2742.
20. David C.S., Atassi M.Z. Genetic control and intersite influences on the immune response to sperm whale myoglobin. Adv. Exp. Med. Biol. 1982, 150:97-125.
21. Das Gupta B.R., Sugiyama H. Role of a protease in natural activation of Clostridium botulinum neurotoxin. Infect. Immun. 1972, 6(4):587-590.
22. Dertzbaugh M.T., West M.W. Mapping of protective and crossreactive domains of the type A neurotoxin of Clostridium botulinum. Vaccine 1996, 14(16):1538-1544.
23. Dickson E.C., Shevky R. Botulism studies on the manner in which the toxin of Clostridium botulinum acts upon the body. II. The effect on the voluntary nervous system. J. Exp. Med. 1923, 38(4):327-346.
24. Dickson E.C., Shevky R. Botulism studies on the manner in which the toxin of Clostridium botulinum acts upon the body. I. The effect upon the autonomic nervous system. J. Exp. Med. 1923, 37(5):711-731.
25. Dolimbek G.S., Dolimbek B.Z., Aoki K.R., Atassi M.Z. Mapping of the antibody and T cell recognition profiles of the HN domain (residues 449-859) of the heavy chain of botulinum neurotoxin A in two high-responder mouse strains. Immunol. Invest. 2005, 34(2):119-142.
26. Dolimbek B.Z., Aoki K.R., Steward L.E., Jankovic J., Atassi M.Z. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol. Immunol. 2007, 44(5):1029-1041.
27. Dolimbek B.Z., Steward L.E., Aoki K.R., Atassi M.Z. Immune recognition of botulinum neurotoxin B: antibody-binding regions on the heavy chain of the toxin. Mol. Immunol. 2008, 45(4):910-924.
28. Dong J., Thompson A.A., Fan Y., Lou J., Conrad F., Ho M., Pires-Alves M., Wilson B.A., Stevens R.C., Marks J.D. A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region. J. Mol. Biol. 2010, 397(4):1106-1118.
29. Dong M., Yeh F., Tepp W.H., Dean C., Johnson E.A., Janz R., Chapman E.R. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006, 312(5773):592-596.
30. Fu F.N., Lomneth R.B., Cai S., Singh B.R. Role of zinc in the structure and toxic activity of botulinum neurotoxin. Biochemistry 1998, 37(15):5267-5278.
31. Kazim A.L., Atassi M.Z. Structurally inherent antigenic sites. Localization of the antigenic sites of the alpha-chain of human haemoglobin in three host species by a comprehensive synthetic approach. Biochem. J. 1982, 203(1):201-208.
32. Kozaki S., Miyazaki S., Sakaguchi G. Development of anti-toxin with each of two complementary fragments of Clostridium botulinum type B derivative toxin. Infect. Immun. 1977, 18(3):761-766.
33. Kozaki S., Togashi S., Sakaguchi G. Separation of Clostridium botulinum type A derivative toxin into two fragments. Jpn. J. Med. Sci. Biol. 1981, 34(2):61-68.
34. Kozaki S., Miki A., Kamata Y., Ogasawara J., Sakaguchi G. Immunological characterization of papain-induced fragments of Clostridium botulinum type A neurotoxin and interaction of the fragments with brain synaptosomes. Infect. Immun. 1989, 57(9):2634-2639.
35. Krieglstein K.G., DasGupta B.R., Henschen A.H. Covalent structure of botulinum neurotoxin type A: location of sulfhydryl groups, and disulfide bridges and identification of C-termini of light and heavy chains. J. Protein Chem. 1994, 13(1):49-57.
36. Lacy D.B., Tepp W., Cohen A.C., DasGupta B.R., Stevens R.C. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. 1998, 5(10):898-902.
37. Mahrhold S., Rummel A., Bigalke H., Davletov B., Binz T. The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett. 2006, 580(8):2011-2014.
38. Maruta T., Dolimbek B.Z., Aoki K.R., Steward L.E., Atassi M.Z. Mapping of the synaptosome-binding regions on the heavy chain of botulinum neurotoxin A by synthetic overlapping peptides encompassing the entire chain. Protein J. 2004, 23(8):539-552.
39. Middlebrook J.L. Protection strategies against botulinum toxin. Adv. Exp. Med. Biol. 1995, 383:93-98.
40. Najib A., Pelliccioni P., Gil C., Aguilera J. Clostridium neurotoxins influence serotonin uptake and release differently in rat brain synaptosomes. J. Neurochem. 1999, 72(5):1991-1998.
41. Okuda K., Christadoss P.R., Twining S.S., Atassi M.Z., David C.S. Genetic control of immune response to sperm whale myoglobin in mice. I. T lymphocyte proliferative response under H-2-linked Ir gene control. J. Immunol. 1978, 121(3):866-868.
42. Okuda K., Twining S.S., David C.S., Atassi M.Z. Genetic control of immune response to sperm whale myoglobin in mice. II. T lymphocyte proliferative response to the synthetic antigenic sites. J. Immunol. 1979, 123(1):182-188.
43. Schiavo G., Rossetto O., Santucci A., DasGupta B.R., Montecucco C. Botulinum neurotoxins are zinc proteins. J. Biol. Chem. 1992, 267(33):23479-23483.
44. Simpson L.L. Molecular pharmacology of botulinum toxin and tetanus toxin. Ann. Rev. Pharmacol. Toxicol. 1986, 26:427-453.
45. Simpson L.L. Peripheral actions of the botulinum toxins. Botulinum Neurotoxin and Tetanus Toxin 1989, 153-178. Academic Press, New York. L.L. Simpson (Ed.).
46. Stenmark P., Dupuy J., Imamura A., Kiso M., Stevens R.C. Crystal structure of botulinum neurotoxin type A in complex with the cell surface co-receptor GT1b-insight into the toxin-neuron interaction. PLoS Pathog. 2008, 4(8):e1000129.
47. Vaidyanathan V.V., Yishino K., Jahnz M., Dorries C., Bade S., Nauenburg S., Niemann H., Binz T. Proteolysis of SNAP-25 isoforms by botulinum neurotoxin types A, C, and E: domains and amino acid residues controlling the formation of enzyme-substrate complexes and cleavage. J. Neurochem. 1999, 72(1):327-337.
48. Veit M. Molecular biology of neurosecretion and its inhibition by tetanus and botulinum toxins. Berl. Munch. Tierarztl. Wochenschr. 1999, 112(5):186-191.
49. Washbourne P., Pellizzari R., Baldini G., Wilson M.C., Montecucco C. Botulinum neurotoxin types A and E require the SNARE motif in SNAP-25 for proteolysis. FEBS Lett. 1997, 418(1-2):1-5.
50. Woodward L.A., Arimitsu H., Hirst R., Oguma K. Expression of HC subunits from Clostridium botulinum types C and D and their evaluation as candidate vaccine antigens in mice. Infect. Immun. 2003, 71(5):2941-2944.
51. Yoshioka N., Atassi M.Z. Antigenic structure of human haemoglobin: localization of the antigenic sites of the β-chain in three host species by synthetic overlapping peptides representing the entire chain. Biochem. J. 1986, 234(2):441-447.